CAS NO: | 66611-37-8 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Description: BGP-15 HCl is a potent and novel PARP inhibitor that can protect against heart failure and atrial fibrillation in mice. BGP-15 (200 μM) prevents the imatinib mesylate-induced oxidative damages, attenuates the depletion of high-energy phosphates, alters the signaling effect of imatinib mesylate by preventing p38 MAP kinase and JNK activation, and induced the phosphorylation of Akt and GSK-3beta. In-vivo study indicated that BGP-15 improved cardiac function and reduced arrhythmic episodes in two HF and AF mouse models. In these models, BGP-15 was associated with increased phosphorylation of IGF1R. References: Am J Pathol. 2016;186:3246-3260; Sci Transl Med. 2016;8(350):350ra103; Nat Commun. 2014;5:5705. Related CAS #: 66611-37-8 (HCl) 66611-38-9 (free base)
纯度:≥98%
CAS:66611-37-8